Lotilan

Products

Lotilaner was approved in the EU in 2017 and in the U.S. and many countries in 2018 in chewable tablet form for dogs and as chewable tablets for cats (Credelio).

Structure and properties

Lotilaners (C20H14Cl3F6N3O3S, Mr = 596.8 g/mol) belongs to the isoxazoline group and exists as a pure -enantiomer.

Effects

Lotilaner (ATCvet QP53BE04) has antiparasitic (insecticidal and acaricidal) properties against fleas and ticks and is effective during one month. The effects are due to inhibition of GABA-gated chloride channels, leading to uncontrolled neuromuscular activity and rapid death of parasites. Lotilaner has a long terminal half-life of about 4 weeks. The parasites ingest the active ingredient while sucking blood. Effects occur within 12 to 24 hours.

Indications

  • For the treatment of flea and tick infestation in dogs.
  • For the treatment of a flea and tick infestation in cats.

Dosage

According to the professional information. The tablets are administered once a month with or after feeding and according to the weight of the animal.

Contraindications

  • Hypersensitivity

For complete precautions, see the drug label.

Interactions

Interactions are not known to date, according to the SmPC.

Adverse effects

Adverse effects are not known to date according to the SmPC.